Interim results from a global, randomized phase II study in people with previously treated non-small cell lung cancer showed that the immunotherapy MPDL3280A doubled the overall survival (HR=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
